



Platythorax increases residual volume/total lung capacity in idiopathic pleuroparenchymal fibroelastosis

Copyright ©The authors 2024

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

Received: 11 Dec 2023
Accepted: 25 Feb 2024

To the Editor:

Idiopathic pleuroparenchymal fibroelastosis (iPPFE) is a chronic progressive interstitial lung disease (ILD) characterised by upper lobe-dominant elastofibrosis [1]. Patients with iPPFE exhibit physical features such as emaciation, platythorax and deepened suprasternal notch [1]. In most patients with restrictive lung disease, the vital capacity (VC), residual volume (RV) and total lung capacity (TLC) decrease proportionately without affecting the RV/TLC ratio [2, 3]. Pulmonary physiology in patients with iPPFE is notable due to the markedly decreased VC and increased RV/TLC ratio [1, 4–6]. This deviation from the typical pattern observed in most patients with restrictive lung diseases raises questions regarding the mechanism underlying increased RV/TLC ratio in patients with iPPFE. Researchers have postulated that platythorax and hyperinflation in the lower lobes are potential contributors to an increase in the RV/TLC ratio in patients with iPPFE [4, 6–11]. This study aimed to elucidate the mechanism underlying the increase in the RV/TLC ratio in patients with iPPFE.

We conducted an observational retrospective study including patients diagnosed with iPPFE between 2011 and 2022 at the Fukuoka University Chikushi Hospital (Japan). The inclusion criteria were patients aged ≥ 20 years who were diagnosed according to the proposed criteria for iPPFE [5], and who underwent simultaneous chest computed tomography (CT) and pulmonary function tests at diagnosis. Patients with concurrent pneumonia, pneumothorax, pneumomediastinum or lung cancer detected on CT examination at diagnosis were excluded. We estimated the flat chest index as the radiological extent of platythorax [8, 12]. The flat chest index was defined as the ratio of the anteroposterior diameter of the right thoracic cage to the transverse diameter of the thoracic cage on chest CT images at the level of the sixth thoracic vertebra, as previously described [8, 12]. ILD complicated in the lower lobes of patients with iPPFE was defined as any fibrotic lesion other than PPFE in the lower lobes. Three-dimensional (3D) images were constructed and volumetric analysis was performed to quantify lung volume in each lobe using SYNAPSE VINCENT (version 5.3; Fujifilm Medical Systems, Tokyo, Japan). The quantified lung volumes were standardised by dividing them by the predicted value of forced vital capacity (FVC), as previously described [13]. If a patient underwent CT or pulmonary function tests 12 \pm 6 months after diagnosis, the annual changes in standardised lung volume, flat chest index and pulmonary function parameters were calculated using the following formula:

$$\text{Annual change in parameter} = \frac{(\text{value at } 12 \pm 6 \text{ months after diagnosis}) - (\text{value at diagnosis})}{\text{interval, years}}$$

Continuous data are presented as mean \pm SD. The paired t-test or Wilcoxon test was used to evaluate differences in paired data. Pearson's correlation coefficients were used to examine the associations between the parameters. Statistical significance was set at $p < 0.05$. All statistical analyses were performed using the R software (version 4.1.0; R Foundation for Statistical Computing, Vienna, Austria).

This study consisted of 57 patients with iPPFE (38 men and 19 women) with a mean age of 72.7 years. The body mass index was 17.9 \pm 3.11 kg·m⁻², FVC 69.3 \pm 23.0% pred, forced expiratory volume in 1 s (FEV₁)/FVC 90.4 \pm 9.39%, RV 93.3 \pm 26.9% pred, TLC 80.9 \pm 19.1% pred, RV/TLC 118 \pm 29.6% pred and diffusion capacity for carbon monoxide 94.3 \pm 33.9% pred.



Shareable abstract (@ERSpublications)

Platythorax significantly contributes to the increase in residual volume/total lung capacity ratio in patients with idiopathic pleuroparenchymal fibroelastosis <https://bit.ly/3uZ0rmP>

Cite this article as: Kinoshita Y, Takenaka S, Takata K, *et al*. Platythorax increases residual volume/total lung capacity in idiopathic pleuroparenchymal fibroelastosis. *ERJ Open Res* 2024; 10: 00996-2023 [DOI: 10.1183/23120541.00996-2023].

Correlation analysis between the flat chest index and pulmonary function parameters at diagnosis showed that the flat chest index positively correlated with FVC % pred ($r=0.557$, $p<0.001$) and TLC % pred ($r=0.548$, $p<0.001$), and inversely correlated with RV/TLC % pred ($r=-0.404$, $p=0.007$) (figure 1a). Furthermore, in the analyses of annual changes, the flat chest index positively correlated with FVC % pred ($r=0.469$, $p=0.008$) and TLC % pred ($r=0.494$, $p=0.032$), and inversely correlated with RV/TLC % pred ($r=-0.526$, $p=0.021$) (figure 1a). The RV/TLC % pred increases in patients with obstructive lung disease or air trapping, as well as in those with platythorax or hyperinflation [2, 3]. To investigate their influence, we examined the correlation between RV/TLC %pred and FEV₁/FVC and between RV/TLC %pred and VC-FVC. However, no correlations were observed between RV/TLC % pred and FEV₁/FVC ($r=0.247$, $p=0.111$), or between RV/TLC % pred and VC-FVC ($r=-0.012$, $p=0.935$) at diagnosis.

The annual changes in standardised lung volume were quantified in 42 patients. Among the 42 patients or patients with iPPFE with ILD in the lower lobes ($n=25$), standardised total lung volume, upper-lobe volume and lower-lobe volume decreased significantly between diagnosis and 12±6 months after diagnosis (figure 1b). In patients with iPPFE without ILD in the lower lobes ($n=17$), the standardised total lung volume and lower-lobe volume were equivalent between diagnosis and 12±6 months after diagnosis, but upper-lobe volume decreased significantly. An increase in the standardised lower-lobe volume between diagnosis and 12±6 months after diagnosis was observed in 10 (23.8%) of the 42 patients. We compared the clinical characteristics between patients with increased lower-lobe volume and those with decreased lower-lobe volume. However, there were no significant differences in the clinical characteristics between the groups.



Correlation analysis between standardised lung volume and pulmonary function parameters at diagnosis showed moderate or strong correlations between the standardised total lung volume and FVC % pred ($r=0.665$), RV % pred ($r=0.643$) and TLC % pred ($r=0.877$); between upper-lobe volume and FVC % pred ($r=0.416$) and TLC % pred ($r=0.545$); and between lower-lobe volume and RV % pred ($r=0.552$) and TLC % pred ($r=0.578$) (figure 1c). In the analyses of annual changes, moderate or strong correlations were found between the standardized total lung volume and FVC % pred ($r=0.613$) and TLC % pred ($r=0.613$), upper-lobe volume and FVC % pred ($r=0.590$), and lower-lobe volume and FVC % pred ($r=0.410$) and TLC % pred ($r=0.674$) (figure 1c). However, no correlation was observed between RV/TLC % pred and standardised lung volume at diagnosis and in an annual change analysis.

Patients with iPPFE have a markedly decreased VC, mild decrease in TLC, and normal or mildly increased RV, resulting in an increased RV/TLC % pred [6]. This distinctive pattern is labelled as “complex restriction pattern” and is associated with conditions that impair lung emptying, such as chest wall restriction, occult obstruction or neuromuscular disease [2, 3]. The causes of chest wall restriction include chest wall deformities (congenital or acquired), burn scars on the chest wall, obesity and respiratory muscle weakness [3, 14]. Although the previous study showed that the flat chest index correlated with RV/TLC % pred at diagnosis in patients with iPPFE [15], this study showed that the flat chest index consistently and inversely correlated with RV/TLC % pred in patients with iPPFE, not only at diagnosis but also in the annual change analysis. Therefore, it is reasonable to postulate that chest wall restriction contributes to the increase in RV/TLC % pred in patients with iPPFE.

Decreased compliance of the upper lobes in patients with iPPFE could trigger compensatory hyperinflation in the lower lobes [7]. FUKADA *et al.* [13] measured lung volume in patients with iPPFE using 3D-CT and showed that the standardised lower-lung volume were larger in patients with iPPFE without ILD in the lower lobes compared to healthy controls. The present study showed that 23.8% of patients with iPPFE exhibited an increase in standardised lower-lung volume during 1-year follow-up. Therefore, in some patients with iPPFE, the lower lobes may be inflated over time. Meanwhile, as our study revealed no correlation between the standardised lower-lobe volume and RV/TLC % pred, hyperinflation is unlikely to contribute to the increase in RV/TLC % pred in patients with iPPFE.

The present study had several limitations. First, this was a single-centre retrospective study with a relatively small number of patients because of the rarity of the disease, potentially introducing patient selection bias. Second, the 1-year interval may be too short to examine time-dependent changes in lung volume in patients with iPPFE. Nonetheless, given the progressive nature of PPFE, with a poor prognosis, further extension of the interval may have increased the number of deaths and made the analysis more difficult.

In conclusion, the flat chest index consistently and inversely correlated with RV/TLC % pred at diagnosis and in an annual change analysis among patients with iPPFE. Meanwhile, no correlation was found between the standardized lower-lobe volume and RV/TLC % pred in patients with iPPFE. Hence, the



c)

	FVC % pred	RV % pred	TLC % pred	RV/TLC % pred
At diagnosis				
Standardised total lung volume	0.665*	0.643*	0.877*	-0.046
Standardised upper lobe volume	0.416*	0.337*	0.545*	0.04
Standardised lower lobe volume	0.377*	0.552*	0.578*	-0.016
Annual change				
Standardised total lung volume	0.677*	0.185	0.613*	-0.168
Standardised upper lobe volume	0.59*	0.015	0.381	-0.278
Standardised lower lobe volume	0.41*	0.272	0.674*	-0.098

r

FIGURE 1 a) Correlation between the flat chest index and each pulmonary function parameter in patients with idiopathic pleuroparenchymal fibroelastosis (iPPFE). The upper panels show the scatterplot at diagnosis and the lower panels show the annual change analyses. b) Standardised total lung volumes, upper-lung volumes and lower-lung volumes at diagnosis and 12±6 months after diagnosis in patients with iPPFE. In patients with iPPFE, the standardised total lung volume, upper-lobe volume and lower-lobe volume decreased significantly between diagnosis and 12±6 months after diagnosis (118±23.3% versus 104±27.6%, $p<0.001$; 34.4±13.7% versus 28.9±12.6%, $p<0.001$; 69.7±21.4% versus 63.1±21.9%, $p<0.001$). In patients with iPPFE with interstitial lung disease (ILD) in the lower lobes, the standardised total lung volume, upper-lobe volume, and lower-lobe volume also decreased significantly (111±21.6% versus 94.8±22.8%, $p<0.001$; 35.0±15.1% versus 28.3±13.5%, $p<0.001$; 61.9±19.7% versus 53.6±6.2%, $p<0.001$). In patients with iPPFE without ILD in the lower lobes, the standardised total lung volume and lower-lobe volume were equivalent (132±20.9% versus 124±26.1%, $p=0.111$; 85.3±16.0% versus 82.1±19.6%, $p=0.251$), but upper-lobe volume decreased significantly (33.4±10.6% versus 30.0±10.9%, $p=0.022$). *: $p<0.05$. c) Correlation coefficients (r) between pulmonary function parameters and standardised lung volume in patients with iPPFE. FVC: forced vital capacity; RV: residual volume; TLC: total lung capacity. *: $p<0.05$.

platythorax plays a central role in increasing RV/TLC in patients with iPPFE. Understanding these mechanisms sheds light on the complex physiology of patients with iPPFE and has implications for its diagnosis and management.

Yoshiaki Kinoshita , Shota Takenaka, Kengo Takata, Takuhide Utsunomiya, Yohei Koide , Kenji Wada, Yuji Yoshida, Shota Nakashima, Hisako Kushima and Hiroshi Ishii 

Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Chikushino, Japan.

Corresponding author: Hiroshi Ishii (hishii@fukuoka-u.ac.jp)

Provenance: Submitted article, peer reviewed.

Data availability: All data generated or analysed during this study are included in this published article. The datasets used and/or analysed during the current study are available from the corresponding author on request.

Ethics statement: The Fukuoka University Hospital Institutional Review Board approved the study protocol (approval number C20-09-002).

Author contributions: Y. Kinoshita: conceptualisation, data curation, investigation, writing (original draft, and review and editing) and final approval of the manuscript. S. Takenaka, K. Takata, Y. Koide, T. Utsunomiya, K. Wada, Y. Yoshida, S. Nakashima and H. Kushima: data curation, writing (review and editing) and final approval of the manuscript. H. Ishii: conceptualisation, investigation, writing (original draft, and review and editing), supervision, project administration and final approval of the manuscript.

Conflict of interest: The authors declare no conflicts of interest in association with the present study.

Support statement: This work was supported in part by JSPS KAKENHI (grant number 21K16153). Funding information for this article has been deposited with the Crossref Funder Registry.

References

- 1 Chua F, Desai SR, Nicholson AG, *et al.* Pleuroparenchymal fibroelastosis. A review of clinical, radiological, and pathological characteristics. *Ann Am Thorac Soc* 2019; 16: 1351–1359.
- 2 Stanojevic S, Kaminsky DA, Miller MR, *et al.* ERS/ATS technical standard on interpretive strategies for routine lung function tests. *Eur Respir J* 2022; 60: 2101499.
- 3 Clay RD, Iyer VN, Reddy DR, *et al.* The “complex restrictive” pulmonary function pattern: clinical and radiologic analysis of a common but previously undescribed restrictive pattern. *Chest* 2017; 152: 1258–1265.
- 4 Ikeda T, Kinoshita Y, Ueda Y, *et al.* Physiological criteria are useful for the diagnosis of idiopathic pleuroparenchymal fibroelastosis. *J Clin Med* 2020; 9: 3761.
- 5 Kinoshita Y, Utsunomiya T, Wada K, *et al.* Comparative study of the two diagnostic criteria for idiopathic pleuroparenchymal fibroelastosis. *Respir Med Res* 2023; 84: 101046.
- 6 Ishii H, Kinoshita Y, Kushima H, *et al.* The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis. *Chron Respir Dis* 2019; 16: 147997311986794.
- 7 Yoshida Y, Nagata N, Tsuruta N, *et al.* Heterogeneous clinical features in patients with pulmonary fibrosis showing histology of pleuroparenchymal fibroelastosis. *Respir Invest* 2016; 54: 162–169.

- 8 Harada T, Yoshida Y, Kitasato Y, *et al.* The thoracic cage becomes flattened in the progression of pleuroparenchymal fibroelastosis. *Eur Respir Rev* 2014; 23: 263–266.
- 9 Watanabe K. Pleuroparenchymal fibroelastosis: its clinical characteristics. *Curr Respir Med Rev* 2013; 9: 229–237.
- 10 Ricoy J, Suárez-Antelo J, Antúnez J, *et al.* Pleuroparenchymal fibroelastosis: clinical, radiological and histopathological features. *Respir Med* 2022; 191: 106437.
- 11 Kusagaya H, Nakamura Y, Kono M, *et al.* Idiopathic pleuroparenchymal fibroelastosis: consideration of a clinicopathological entity in a series of Japanese patients. *BMC Pulm Med* 2012; 12: 72.
- 12 Ikeda T, Kinoshita Y, Miyamura T, *et al.* Platythorax progresses with lung involvement in pleuroparenchymal fibroelastosis. *Respir Investig* 2022; 60: 293–299.
- 13 Fukada A, Suzuki Y, Mori K, *et al.* Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume. *Eur Respir J* 2022; 60: 2200637.
- 14 Chalker RB, Dickey BF, Rosenthal NC, *et al.* Extrapulmonary thoracic restriction (hidebound chest) complicating eosinophilic fasciitis. *Chest* 1991; 100: 1453–1455.
- 15 Ishii H, Watanabe K, Kushima H, *et al.* Pleuroparenchymal fibroelastosis diagnosed by multidisciplinary discussions in Japan. *Respir Med* 2018; 141: 190–197.